Cytokine gene expression signature in ovarian clear cell carcinoma

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1094-1100

  Yanaihara, Nozomu ^a   Anglesio, Michael S ^b   Ochiai, Kazunori ^a   Hirata, Yukihiro ^a   Saito, Misato ^a   Nagata, Chie ^a   Iida, Yasushi ^a   Takakura, Satoshi ^a   Yamada, Kyosuke ^a   Tanaka, Tadao ^a   Okamoto, Aikou ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Clear cell carcinoma; Cytokine; Expression signature; IL 6; Stat3

Indexed keywords

CISPLATIN; COLONY STIMULATING FACTOR 1; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DPA1 ANTIGEN; HLA DRA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; PACLITAXEL; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOCRINE EFFECT; CANCER CHEMOTHERAPY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLUSTER ANALYSIS; DRUG CYTOTOXICITY; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TH2 CELL;

CELL LINE, TUMOR; CYTOKINES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MULTIGENE FAMILY; OVARIAN NEOPLASMS; OVARY; RNA INTERFERENCE; RNA, SMALL INTERFERING; SARCOMA, CLEAR CELL; STAT3 TRANSCRIPTION FACTOR; TH2 CELLS; TRANSCRIPTOME;

EID: 84865023635     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1533     Document Type: Article

References (29)

1. Vaughan S, Coward JI, Bast RC Jr, et al: Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 23: 719-725, 2011.
2. Köbel M, Kalloger SE, Boyd N, et al: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232, 2008.
3. Swenerton KD, Santos JL, Gilks CB, et al: Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol 22: 341-347, 2010.
4. Gilks CB, Ionescu DN, Kalloger SE, et al: Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39: 1239-1251, 2008.
5. Anglesio MS, Carey MS, Köbel M, et al: Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010 (Review). Gynecol Oncol 121: 407-415, 2010.
6. Takakura S, Takano M, Takahashi F, et al: Japanese Gynecologic Oncology Group. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 20: 240-247, 2010.
7. Shimada M, Kigawa J, Ohishi Y, et al: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 113: 331-334, 2009.
8. Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion (Review). Science 331: 1565-1570, 2011.
9. Nelson BH: The impact of T-cell immunity on ovarian cancer outcomes (Review). Immunol Rev 222: 101-116, 2008.
10. Kusuda T, Shigemasa K, Arihiro K, et al: Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 13: 1153-1158, 2005.
11. Marth C, Fiegl H, Zeimet AG, et al: Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 191: 1598-1605, 2004. (Pubitemid 39491185)
12. Seike M, Yanaihara N, Bowman ED, et al: Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 99: 1257-1269, 2007. (Pubitemid 47299904)
13. Kurman RJ and Shih IeM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum Pathol 42: 918-931, 2001.
14. Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25: 169-193, 2000.
15. Li N, Grivennikov SI and Karin M: The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 12: 429-431, 2011.
16. Itamochi H, Kigawa J and Terakawa N: Mechanisms of chemo-resistance and poor prognosis in ovarian clear cell carcinoma (Review). Cancer Sci 99: 653-658, 2008. (Pubitemid 351448066)
17. Tsiatas ML, Gyftaki R, Liacos C, et al: Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. Int J Gynecol Cancer 19: 1329-1334, 2009.
18. Tothill RW, Tinker AV, George J, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208, 2008.
19. Anglesio MS, George J, Kulbe H, et al: IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 17: 2538-2548, 2011.
20. Yamaguchi K, Mandai M, Oura T, et al: Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29: 1741-1752, 2010.
21. Hong DS, Angelo LS and Kurzrock R: Interleukin-6 and its receptor in cancer: implications for translational therapeutics (Review). Cancer 110: 1911-1928, 2007. (Pubitemid 350036849)
22. Nilsson MB, Langley RR and Fidler IJ: Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65: 10794-10800, 2005. (Pubitemid 41713347)
23. Rabinovich A, Medina L, Piura B, Segal S and Huleihel M: Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res 27: 267-272, 2007. (Pubitemid 46363341)
24. Jones S, Wang TL, Shih IeM, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231, 2010.
25. Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543, 2010.
26. Cullen SJ, Ponnappan S and Ponnappan U: Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes. Mol Immunol 47: 600-605, 2009.
27. Wang Y, Niu XL, Qu Y, et al: Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295: 110-123, 2010.
28. Guo Y, Nemeth J, O'Brien C, et al: Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 16: 5759-5769, 2010.
29. Coward J, Kulbe H, Chakravarty P, et al: Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17: 6083-6096, 2011.